4DMedical (4DX, $1.58)Market capitalisation: $418 millionThree-year total return: n/aAnalysts’ consensus target price: $1.70 (Thomson Reuters) Imaging company 4DMedical (4DX) surged on to the ASX screens in its August float, at a 100% “pop.” Issued in the prospectus at 73 cents, the shares opened for trade on August 7 at $1.47, and reached $1.70 in August…
It seems as if Japan does not get a lot of respect from external investors, for good reasons. The Nikkei index appears to disprove the theory that the sharemarket delivers superior long-term investment returns, being at the same level now that it was back in 1991. Almost 31 years on from its record high, the…
Semiconductors would have to be one of the most pervasive and critical pieces of technology in our daily lives – but they are usually not thought about very much. They certainly don’t seem to get the investment love like they should, or get talked about as much as, say, the FAANG stocks or electric vehicle…
Troy is a Partner and Adviser at Koda Capital. Troy is a FASEA-compliant financial adviser holding a Bachelor of Commerce and SMSF Specialist Adviser designation. He became a member of the Inside Network and an inaugural member of the Advisrry Committee; seeking to learn from his peers and share his own wisdom from many years in the industry.
It’s hardly a fair comparison, is it? To put REA Group alongside Domain Holdings?
In the first of a series on Australian biotech success stories, we start with some of the outstanding medical device stocks on the ASX.
With July coming to a close, it’s time for reporting season – and this year, it’s not going to be pretty.
While more and more Australian investors get comfortable with investing overseas, it’s fair to assume that Latin America is not on most people’s map of the investable universe – “there be dragons,” as the old mariners used to say.
Investors are realising that without meaningful technology exposure, their portfolios are missing a major growth driver. However, the difficulty of picking individual stocks should not be under-estimated, with the innovations and business models of many tech stocks hard to grapple with.
The COVID-19 pandemic has begun to bite into the residential property market, with capital city dwelling values falling a cumulative 1.3% over the past two months – but this mild weakening could be just the start of a double-digit decline. Â
